Pharvaris (NASDAQ:PHVS) Price Target Lowered to $51.00 at Royal Bank Of Canada

Pharvaris (NASDAQ:PHVS) had its price objective cut by Royal Bank Of Canada from $52.00 to $51.00 in a report issued on Monday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other research firms have also recently issued reports on PHVS. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. Finally, Wall Street Zen cut shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Sunday. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.60.

Pharvaris Stock Down 0.7%

NASDAQ:PHVS opened at $28.37 on Monday. The company has a fifty day simple moving average of $27.07 and a two-hundred day simple moving average of $25.47. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -8.42 and a beta of -2.58. Pharvaris has a 52 week low of $11.51 and a 52 week high of $29.85.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System lifted its position in Pharvaris by 2.2% in the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after acquiring an additional 520 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the last quarter. HighVista Strategies LLC lifted its position in Pharvaris by 4.3% in the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock valued at $418,000 after acquiring an additional 971 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Pharvaris in the fourth quarter valued at $35,000. Finally, Public Employees Retirement System of Ohio lifted its position in Pharvaris by 20.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after acquiring an additional 1,300 shares during the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.